This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
Pediatric hematology and oncology · 2019
Latest funding
- $918,000
Harnessing infection-associated modifiers of paediatric acute lymphoblastic leukaemia progression for therapeutic benefit
CIHR · 2024 · Nominated PI
- $100,000
Harnessing infection-associated modifiers of paediatric acute lymphoblastic leukaemia progression for therapeutic benefit
CIHR · 2023 · Nominated PI
- $1,028,925
Targeting CD47 in pediatric acute lymphoblastic leukemia.
CIHR · 2020 · Co-investigator
1 publications.
The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
Ronsley R, Kariminia A, Ng B, Mostafavi S, Reid G, Subrt P, Hijiya N, Schultz KR
Harnessing infection-associated modifiers of paediatric acute lymphoblastic leukaemia progression for therapeutic benefit
Principal investigators: Reid, Gregor
Keywords: Acute Lymphoblastic Leukemia; Early-Life Infection; Mouse Models Of Cancer; Neonatal Immunity; Pediatric Cancer; Pre-Clinical Therapy Development
Harnessing infection-associated modifiers of paediatric acute lymphoblastic leukaemia progression for therapeutic benefit
Principal investigators: Reid, Gregor
Keywords: Acute Lymphoblastic Leukemia; Early-Life Infection; Mouse Models Of Cancer; Neonatal Immunity; Pediatric Cancer; Pre-Clinical Therapy Development
Targeting CD47 in pediatric acute lymphoblastic leukemia.
Principal investigators: Lim, Chinten J
Keywords: Cd47; Cell Death; Cell Survival; Chemotherapy; Leukemia; Macrophages; Oncogenic Drivers; Phagocytosis; Proteomics; Signal Transduction
Identifying infection-induced determinants of paediatric acute lymphoblastic leukaemia progression
Principal investigators: Reid, Gregor
Keywords: Acute Lymphoblastic Leukemia; Early-Life Infection; Mouse Models Of Cancer; Neonatal Immunity; Pediatric Cancer
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
Principal investigators: Li, Shyh-Dar; Rassekh, Shahrad R
Keywords: Anticancer Drug Delivery; Lipid Nanoparticles; Oral Pediatric Formulation; Oro-Dispersible Formulation
Integrin signaling in cell adhesion mediated drug resistance in pediatric acute leukemias.
Principal investigators: Lim, Chinten J
Keywords: Acute Lymphoblastic Leukemia; Calcium Signaling; Calreticulin; Cell Survival And Proliferation; Cell-Substratum Adhesion; Chemoresistance; Integrins; T-Cells; Tumour Markers; Tumour Microenvironment
Identifying Determinants of Acute Lymphoblastic Leukemia Progression
Principal investigators: Reid, Gregor
Keywords: Animal Model; Cancer Immunotherapy; Cancer Prevention; Carcinogenesis; Chldhood Leukemia; Host-Tumour Interaction; Pre-Leukemia
The Annual Vaginal Microbiome Group Initiative (VOGUE) Workshop
Principal investigators: Money, Deborah M
Keywords: Canadian Microbiome Initiative; Clinical Genomics; Maternal And Child Health; Vaginal Microbiome; Women'S Health
Maternal-Infant Microbiome and Immunity (MIMI) Network
Principal investigators: Kollmann, Tobias R
Keywords: Global Health; Immunology; Maternal Health; Microbiome; Pediatrics
The Vaginal Microbiome Project Team
Principal investigators: Money, Deborah M; Bocking, Alan D; Hemmingsen, Sean M; Hill, Janet E; Reid, Gregor
Keywords: Bacterial Vaginosis; Gynecology; Infection; Microbiome; Preterm Birth; Women'S Health
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.